title: How will new and future therapies change our treatment of IBD?
abstract: Fundamental insights into the pathogenesis of inflammatory bowel diseases (IBD) have led to the development of new therapies and lots of experimental compounds in the pipeline. Our treatment of IBD is therefore constantly evolving. In this editorial, we postulate that bi- or even polyspecific therapy will be an important mainstay of future IBD treatment. Moreover, we highlight some promising new therapeutic concepts currently under investigation and point at the outstanding and growing importance of personalized medicine to assign drugs from the increasing pool of options to the individual patient.
authors.affiliation: a Department of Medicine 1 , University of Erlangen-Nuremberg, Kussmaul Campus for Medical Research & Translational Research Center , Erlangen , Germany.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Zundler
authors.affiliation: a Department of Medicine 1 , University of Erlangen-Nuremberg, Kussmaul Campus for Medical Research & Translational Research Center , Erlangen , Germany.
authors.forename: Markus F
authors.initials: MF
authors.lastname: Neurath
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016207:Cytokines / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015212:Inflammatory Bowel Diseases / Q000276:immunology / Q000628:therapy*; D057285:Precision Medicine
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines
keywords: cytokines; gut homing; immunology; inflammatory bowel diseases; personalized medicine